Nephropathy in Diabetes
暂无分享,去创建一个
[1] M. Cooper,et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.
[2] T. Nicotera,et al. Oxidative damage to DNA in diabetes mellitus , 1996, The Lancet.
[3] L. Groop,et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. , 1994, JAMA.
[4] M. Seldin,et al. Mexican-American admixture mapping analyses for diabetic nephropathy in type 2 diabetes mellitus. , 2010, Seminars in nephrology.
[5] G. Blohmé,et al. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] B. Kestenbaum,et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. , 2007, Journal of the American Society of Nephrology : JASN.
[7] E. Lewis,et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] P. O'Malley,et al. Meta-Analysis: The Effect of Statins on Albuminuria , 2006, Annals of Internal Medicine.
[9] C. Mogensen,et al. The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy , 1983, Diabetes.
[10] S. Kawazu,et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. , 1994, Journal of diabetes and its complications.
[11] S. Mauer,et al. Structural-functional correlations of diabetic nephropathy. , 1994, Kidney international.
[12] B. Satirapoj. Review on pathophysiology and treatment of diabetic kidney disease. , 2010, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[13] M. Cooper,et al. Agents in development for the treatment of diabetic nephropathy , 2008, Expert opinion on emerging drugs.
[14] L. Groop,et al. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria , 1996 .
[15] E. Morales,et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] H. van Goor,et al. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. , 2007, Kidney international.
[17] R. Trevisan,et al. Genetic factors in the development of diabetic nephropathy. , 1995, The Journal of laboratory and clinical medicine.
[18] Jai Radhakrishnan,et al. Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[19] H. Ha,et al. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.
[20] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[21] H. Parving,et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. , 1992, Kidney international.
[22] G. Wolf,et al. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. , 2008, Current diabetes reviews.
[23] S. Yusuf,et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.
[24] H. Parving,et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. , 2002, Kidney international.
[25] C. Delcroix,et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. , 2005, Journal of the American Society of Nephrology : JASN.
[26] R. Bain,et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] Kdoqi. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] H. Ha,et al. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. , 2008, Diabetes research and clinical practice.
[29] G. Remuzzi,et al. Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.
[30] H. Parving,et al. Beneficial impact of spironolactone in diabetic nephropathy. , 2005, Kidney international.
[31] E. Ritz,et al. Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.
[32] H. Haller,et al. Inhibition of protein kinase C in diabetic nephropathy--where do we stand? , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[33] D. Sutherland,et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. , 2006, Kidney international.
[34] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[35] S. Adler,et al. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. , 2006, Kidney international.
[36] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[37] G. Jerums,et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. , 2002, Diabetes care.
[38] M. Province,et al. Prevention of Hemodynamic and Vascular Albumin Filtration Changes in Diabetic Rats by Aldose Reductase Inhibitors , 1989, Diabetes.
[39] P. Raskin,et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. , 1991, The New England journal of medicine.
[40] H. Parving,et al. Prevention of diabetic renal disease with special reference to microalbuminuria , 1995, The Lancet.
[41] G. Navis,et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. , 2008, Journal of the American Society of Nephrology : JASN.
[42] H. Parving,et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes , 1988, British medical journal.
[43] A. Krolewski,et al. Familial factors determine the development of diabetic nephropathy in patients with IDDM , 1996, Diabetologia.
[44] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[45] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[46] B. Zinman,et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.
[47] L. Groop,et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria , 1994 .
[48] J. Mustonen,et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.
[49] Norman Fleischer,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .
[50] R. Elston,et al. Genome-Wide Scans for Diabetic Nephropathy and Albuminuria in Multiethnic Populations , 2007, Diabetes.
[51] P. Rossing. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005 , 2005, Diabetologia.
[52] H. Kobori,et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. , 2005, Journal of the American Society of Nephrology : JASN.
[53] T. Meyer,et al. Podocyte loss and progressive glomerular injury in type II diabetes. , 1997, The Journal of clinical investigation.
[54] G. Bakris,et al. Effects of Sodium Intake on Albumin Excretion in Patients with Diabetic Nephropathy Treated with Long-Acting Calcium Antagonists , 1996, Annals of Internal Medicine.
[55] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[56] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[57] E. Ritz,et al. Diabetic nephropathy in type II diabetes. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[58] S. Bianchi,et al. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[59] J. Ingelfinger,et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. , 2007, Kidney international.
[60] T. Kern,et al. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. , 2005, Kidney international.
[61] B. Brenner,et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.
[62] B. Zinman,et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.
[63] S. Araki,et al. Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. , 1995, Journal of diabetes and its complications.
[64] B. Hoogwerf,et al. Consensus Development Conference on the Diagnosis and Management of Nephropathy in Patients with Diabetes Mellitus , 1994, Diabetes Care.
[65] N. Bank. Mechanisms of diabetic hyperfiltration. , 1991, Kidney international.
[66] C. Deerochanawong,et al. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[67] Ashutosh Kumar Singh,et al. Effect of glycated proteins on the matrix of glomerular epithelial cells. , 1998, Journal of the American Society of Nephrology : JASN.
[68] S. Freytag,et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. , 1995, The Journal of clinical investigation.
[69] Rury R Holman,et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.
[70] H. Keen,et al. RESTRICTION OF DIETARY PROTEIN AND PROGRESSION OF RENAL FAILURE IN DIABETIC NEPHROPATHY , 1989, The Lancet.
[71] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[72] R. DeFronzo. Diabetic nephropathy: Etiologic and therapeutic considerations , 1995 .
[73] H. Parving. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment , 1998, Diabetologia.
[74] R. Agarwal. Effects of statins on renal function. , 2007, The American journal of cardiology.
[75] H. Parving,et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. , 2005, Diabetes care.
[76] O. Pedersen,et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.
[77] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[78] H. Parving,et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. , 2003, Kidney international.
[79] T. Miyata,et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.
[80] H. King,et al. Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.
[81] Don Poldermans,et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function , 2006, Journal of hypertension.